Recorded Presentation from the NCCN Pharmacy Updates: Maintenance Strategies in the Management of Acute Myeloid Leukemia |
1.00 |
11/26/2024 - 12:00am to 11/26/2025 - 12:00am |
Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma? |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Amyloidosis: Diagnosis, Treatment, and Supportive Care |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Myelodysplastic Syndromes: Treatment Updates and Emerging Data |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Management of TP53 Mutated Mantle Cell Lymphoma |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Diffuse Large B-Cell Lymphoma: Sequencing Therapy for Relapsed/Refractory Disease |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Diagnosis and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease |
2.25 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Chronic Myeloid Leukemia: How to Treat During Pregnancy |
0.25 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updates in Prognosis and Treatment |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Evaluation and Treatment of Primary Central Nervous System Lymphoma |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |